Future cardiology最新文献_第4页

SIRT3 as a potential biomarker and therapeutic target for cardiovascular diseases: a meta-analysis of clinical studies. SIRT3作为心血管疾病的潜在生物标志物和治疗靶点：临床研究的荟萃分析

IF 1

Future cardiology Pub Date : 2025-08-01 Epub Date: 2025-07-04 DOI: 10.1080/14796678.2025.2527535

Nikhil Gupta, Vikas Kumar, Abhinav Kanwal

{"title":"SIRT3 as a potential biomarker and therapeutic target for cardiovascular diseases: a meta-analysis of clinical studies.","authors":"Nikhil Gupta, Vikas Kumar, Abhinav Kanwal","doi":"10.1080/14796678.2025.2527535","DOIUrl":"10.1080/14796678.2025.2527535","url":null,"abstract":"Background: Cardiovascular diseases (CVDs) remain the leading cause of mortality globally, with mitochondrial dysfunction playing a key role in their pathogenesis. SIRT3 (Sirtuin 3), a mitochondrial deacetylase, has emerged as a critical regulator of mitochondrial function and oxidative stress, with evidence linking its reduction to the progression of CVDs. This meta-analysis aimed to evaluate the association between SIRT3 levels and CVDs in order to elucidate its role in CVD pathogenesis and its potential as a biomarker.Methods: A systematic search of MEDLINE and Embase databases was conducted up to August 2024, adhering to PRISMA guidelines. Observational studies evaluating SIRT3 levels in human patients with CVDs as compared to healthy controls were included.Results: 8 studies comprising 397 participants were included in this meta-analysis. Overall, SIRT3 levels were found to be significantly lower in individuals with CVDs compared to healthy controls (SMD: 1.08, 95% CI: 0.495-1.662, p = 0.0032). The reduction in SIRT3 levels was most pronounced in hypertension (SMD: 1.82) and dilated cardiomyopathy (SMD: 1.08).Conclusion: This meta-analysis provides compelling evidence of gsignificantly reduced SIRT3 levels in CVD patients, highlighting its critical role in cardiovascular diseases. These findings underscore the potential of SIRT3 as a biomarker and therapeutic target in CVDs.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"779-788"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144564653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent developments in systemic light-chain amyloidosis prognosis and treatment. 系统性轻链淀粉样变预后及治疗的最新进展。

IF 1

Future cardiology Pub Date : 2025-08-01 Epub Date: 2025-07-12 DOI: 10.1080/14796678.2025.2529701

Adam Ioannou

{"title":"Recent developments in systemic light-chain amyloidosis prognosis and treatment.","authors":"Adam Ioannou","doi":"10.1080/14796678.2025.2529701","DOIUrl":"10.1080/14796678.2025.2529701","url":null,"abstract":"Systemic light-chain (AL) amyloidosis is a rare clonal plasma cell disorder characterized by the production of abnormal immunoglobulin free light-chains that misfold into amyloid fibrils and deposit in the extracellular matrix of tissues. Despite being a multisystemic disease process, the presence and severity of cardiac involvement remains the main determinant of prognosis. Improved understanding of the underlying pathophysiology has resulted in transformative changes in both diagnostics and treatment. Improvements in multimodality cardiac imaging have enabled accurate diagnosis, facilitated rapid initiation of treatment and allowed the direct visualization changes in the myocardial substrate in response to chemotherapy. Significant progress has also been made through leveraging treatments that directly target the underlying abnormal plasma cell clone responsible the production of the amyloidogenic immunoglobulin free light-chains. Current treatment options successfully target amyloid production, but novel anti-amyloid therapies seek to target amyloid fibrils that have already deposited in the organs and facilitate their removal through an immune-mediated degradation process are at advanced stages of development. These treatments have the potential to induce disease regression by depleting amyloid deposits and if successful will represent a significant step forward in the treatment of systemic AL amyloidosis, especially for patients with advanced cardiac disease.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"815-827"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144617233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A study assessing the performance, safety, and durability of a new bioprosthetic aortic valve after up to seven years in the heart: a plain language summary. 一项评估新的生物人工主动脉瓣在心脏中放置长达7年后的性能、安全性和耐久性的研究：简单的语言总结。

IF 1

Future cardiology Pub Date : 2025-08-01 Epub Date: 2025-07-17 DOI: 10.1080/14796678.2025.2523665

Thomas Beaver, Joseph E Bavaria, Bartley Griffith, Lars G Svensson, Philippe Pibarot, Michael A Borger, Omar M Sharaf, David A Heimansohn, Vinod H Thourani, Eugene H Blackstone, John D Puskas

引用次数: 0

The emerging role of artificial intelligence in heart failure. 人工智能在心力衰竭中的新作用。

IF 1

Future cardiology Pub Date : 2025-08-01 Epub Date: 2025-07-03 DOI: 10.1080/14796678.2025.2523155

Brett S Bernstein, Sona Streather, Kevin O'Gallagher

{"title":"The emerging role of artificial intelligence in heart failure.","authors":"Brett S Bernstein, Sona Streather, Kevin O'Gallagher","doi":"10.1080/14796678.2025.2523155","DOIUrl":"10.1080/14796678.2025.2523155","url":null,"abstract":"Heart Failure is a prevalent disease with significant impacts on morbidity and mortality. Heart failure patients have a large volume of healthcare data which is digitized and can be collated. Artificial intelligence (AI) can then be used to assess the data for underlying patterns. AI systems can be trained to analyze readily available data, such as ECGs and heart sounds, and assess likelihood of heart failure. AI can also risk stratify heart failure patients by analyzing available healthcare data. AI can allow rapid assignment of heart failure patients to specific groups via automated echo analysis, but can also provide information regarding novel imaging bio-markers that may be more useful than left ventricular ejection fraction, such as first phase ejection fraction. AI can be used to assess patients' suitability for existing drugs, whilst also enabling development of novel drugs for known or newly discovered drug targets. Heart Failure as a field, with its multi-modal data set and variability in outcomes, will greatly benefit from the expansion and improvement of AI technology over the next 20 years.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"795-801"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7617907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current appraisal of venous excess ultrasound (VExUS) and its applications in the treatment of cardiovascular disease. 静脉过量超声（VExUS）的现状评价及其在心血管疾病治疗中的应用。

IF 1

Future cardiology Pub Date : 2025-08-01 Epub Date: 2025-07-29 DOI: 10.1080/14796678.2025.2530339

Kisha G Thayapran, Radoslaw J Nabrzyski, August A Longino, Edward A Gill

{"title":"Current appraisal of venous excess ultrasound (VExUS) and its applications in the treatment of cardiovascular disease.","authors":"Kisha G Thayapran, Radoslaw J Nabrzyski, August A Longino, Edward A Gill","doi":"10.1080/14796678.2025.2530339","DOIUrl":"10.1080/14796678.2025.2530339","url":null,"abstract":"Bedside assessment of venous congestion is key to managing hospitalized adults with cardiovascular disease and guiding fluid management to achieve euvolemia. Current methods include physical examination, radiographic imaging, and point-of-care ultrasound (POCUS) of the inferior vena cava (IVC). While accessible, physical exam and IVC measurements are prone to errors and variability. Right heart catheterization (RHC), considered the gold standard, is invasive, costly, and often unavailable. A novel ultrasound technique, Venous Excess Ultrasound (VExUS), offers a noninvasive alternative for assessing venous congestion by characterizing the IVC and hepatic, portal, and intrarenal veins. Rapidly evolving literature on VExUS has created controversy and uncertainty around its application to patients with cardiovascular disease. This review summarizes the utility of the VExUS scoring system as a bedside tool for assessing venous congestion in adults with cardiovascular disease. It will discuss the methodology of VExUS, its performance compared to traditional IVC measurements and RHC, and its applications in various cardiovascular conditions including acute decompensated heart failure (ADHF), acute coronary syndromes (ACS), tricuspid regurgitation (TR), cardiorenal syndromes (CRS), cardiogenic shock (CS), and patients undergoing cardiac surgery.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"829-839"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current landscape for connective tissue disease associated-pulmonary arterial hypertension: a focus on right ventricular adaptation and failure. 结缔组织疾病相关肺动脉高压的现状：关注右心室适应和衰竭

IF 1

Future cardiology Pub Date : 2025-08-01 Epub Date: 2025-07-11 DOI: 10.1080/14796678.2025.2529696

Qianwen Wu, Huangshu Ye, Zhangdi Zhou, Miaojia Zhang, Xiaoxuan Sun, Qiang Wang

{"title":"Current landscape for connective tissue disease associated-pulmonary arterial hypertension: a focus on right ventricular adaptation and failure.","authors":"Qianwen Wu, Huangshu Ye, Zhangdi Zhou, Miaojia Zhang, Xiaoxuan Sun, Qiang Wang","doi":"10.1080/14796678.2025.2529696","DOIUrl":"10.1080/14796678.2025.2529696","url":null,"abstract":"Right ventricular (RV) function is the primary determinant of survival in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH). A \"double hit\" hypothesis suggests that RV suffers not only from pressure overload common to all PAH but also from direct insults related to the underlying systemic autoimmunity and inflammation. This likely drives distinct maladaptive remodeling (fibrosis, inflammation) and contributes to the poorer prognosis observed in CTD-PAH compared to idiopathic PAH (IPAH).Comprehensive, multi-modal RV assessment - integrating clinical evaluation, biomarkers, echocardiography, cardiac MRI, and right heart catheterization - is crucial for prognosis and monitoring therapy. RV size, function, and tissue characteristics are key indicators.Current management involves PAH-targeted therapies to reduce RV afterload, optimal CTD control, and supportive care. However, CTD-PAH often shows attenuated treatment responses and worse outcomes, emphasizing the need for therapies directly addressing RV maladaptation. Future research priorities include understanding specific RV injury mechanisms in CTD, refining assessment tools, and developing novel RV-directed strategies. Optimizing outcomes requires a deep understanding of RV pathobiology within the CTD context and integrated, multidisciplinary care.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"803-814"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolution of the management of ultrarare inherited arrhythmias and cardiomyopathies. 罕见遗传性心律失常和心肌病的治疗进展。

IF 1

Future cardiology Pub Date : 2025-08-01 Epub Date: 2025-05-27 DOI: 10.1080/14796678.2025.2508568

Saif Dababneh, Thomas M Roston

引用次数: 0

Treatment options for patients with coronary microvascular dysfunction. 冠状动脉微血管功能障碍患者的治疗选择。

IF 1

Future cardiology Pub Date : 2025-08-01 Epub Date: 2025-06-22 DOI: 10.1080/14796678.2025.2523142

Ian Welch, Brian Case

引用次数: 0

Qualitative analysis of experiences, burdens, and needs among patients with hypertrophic cardiomyopathy in Japan. 日本肥厚性心肌病患者的经历、负担和需求的定性分析。

IF 1

Future cardiology Pub Date : 2025-08-01 Epub Date: 2025-07-11 DOI: 10.1080/14796678.2025.2526279

Yuichiro Maekawa, Yuika Ikeda, Makio Torigoe, Kanako Shimoura, Shintaro Suo, Ryohei Takeda, Hiroaki Kitaoka

{"title":"Qualitative analysis of experiences, burdens, and needs among patients with hypertrophic cardiomyopathy in Japan.","authors":"Yuichiro Maekawa, Yuika Ikeda, Makio Torigoe, Kanako Shimoura, Shintaro Suo, Ryohei Takeda, Hiroaki Kitaoka","doi":"10.1080/14796678.2025.2526279","DOIUrl":"10.1080/14796678.2025.2526279","url":null,"abstract":"Aim: To identify factors affecting the health-related quality of life (HR-QOL) of symptomatic patients with hypertrophic cardiomyopathy (HCM) using qualitative interviews exploring patients' experiences and perceptions.Patients & methods: This cross-sectional observational study was conducted using qualitative web-based or telephone interviews. Adult patients with HCM in Japan who were experiencing burden because of HCM were included. In-depth interviews were conducted using a semi-structured interview guide. The data were analyzed using a thematic analysis approach.Results: Nineteen patients completed the interview. Ten HR-QOL-related themes were identified. Many patients were unaware that they had HCM symptoms, either no longer noticing them following life adjustments or attributing them to factors other than HCM. HCM affected multiple life aspects, including work, family, and social life. Patients resisted disclosing their disease to others and strongly resisted invasive treatment. Patients highly trusted their physicians but were reluctant to discuss their mental burdens and daily life challenges with them.Conclusions: This first qualitative study of HR-QOL in patients with HCM in Japan suggests that deeper physician - patient communication is needed to understand patient burden and needs, as patients have difficulty discussing their burdens with physicians and may lack awareness of HCM symptoms.Clinical trial registration: NCT06181617 (ClinicalTrials.gov).","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"759-768"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case report on myocarditis and right chamber dilation: cardiac magnetic resonance acquisition for accurate diagnosis. 心肌炎合并右室扩张1例：心脏磁共振成像准确诊断。

IF 1

Future cardiology Pub Date : 2025-07-29 DOI: 10.1080/14796678.2025.2537562

Carlos Bertolín-Boronat, Eduardo Baettig, Sergio Torondel, Enrique Santas, Vicente Bodi, Héctor Merenciano-González, Joaquin Gil, Juan Sanchis, Víctor Marcos-Garcés

{"title":"A case report on myocarditis and right chamber dilation: cardiac magnetic resonance acquisition for accurate diagnosis.","authors":"Carlos Bertolín-Boronat, Eduardo Baettig, Sergio Torondel, Enrique Santas, Vicente Bodi, Héctor Merenciano-González, Joaquin Gil, Juan Sanchis, Víctor Marcos-Garcés","doi":"10.1080/14796678.2025.2537562","DOIUrl":"https://doi.org/10.1080/14796678.2025.2537562","url":null,"abstract":"We present the case of a 21-year-old male with chest pain, malaise, and fever, who was initially diagnosed with suspected acute myocarditis. The patient exhibited elevated cardiac troponin levels, occasional premature ventricular complexes, and right ventricular dilation, raising concerns about arrhythmogenic cardiomyopathy. Cardiac magnetic resonance (CMR) imaging showed myocardial edema and subepicardial enhancement in the basal anterolateral segment, confirming myocarditis, but also revealed severe dilation of the right chambers. Advanced imaging sequences identified a previously unrecognized inferior sinus venosus atrial septal defect (SVASD) with partial anomalous pulmonary venous return. This finding led to a significant left-to-right shunt and surgical correction was performed. SVASD, a rare congenital anomaly, often remains undiagnosed due to its subtle clinical presentation and limitations of standard imaging techniques. This case highlights the importance of tailored CMR acquisition protocols, which revealed a congenital heart defect in our patient despite an initial focus on myocarditis. The adjustment in diagnostic approach significantly altered the patient's management and may have improved his long-term prognosis.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-5"},"PeriodicalIF":1.0,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0